Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care infliximab trough-guided dosing in inflammatory bowel disease
ACTRN12616001031459Phase 4Active, not recruiting
- Sponsor
- Alfred Health
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in autoimmune colitis and Crohn's disease, sponsored by Alfred Health. Primary endpoint: Percentage of patients achieving therapeutic infliximab trough concentration. Started Jul 2016; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on ACTRN12616001031459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001031459.